DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Election / Restrictions
In response to the previous restriction requirement, Applicant has chosen to elect Group II for examination, consisting of claims 7-10 & 14-17, without traverse. Applicant has elected species (i), consisting of GmNAS1 protein and SEQ ID NO. 4.
Claim Status
Claims 7-10 & 14-17 are under examination on the merits.
Claims 1-6 & 11-13 are withdrawn as directed to non-elected matter.
Priority
Foreign priority is claimed to CHINA 202211450181.9.
Claims 7-10 & 14-17 receive the U.S. effective filing date of 19 Nov 2022.
Drawings
The drawings are objected to because poor resolution makes labels on Figures 8-10, 13 & 15 illegible.
Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance.
Specification
The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code [¶.3]. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. See MPEP § 608.01.
Claim Rejections - 35 USC § 101
35 U.S.C. 101 reads as follows:
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
Claims 7-10 & 14-17 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. The claims do not fall within at least one of the four categories of patent eligible subject matter because they are directed to ‘an application’. Recitation of ‘an application’ in the claims of the instant application appears to be synonymous with ‘a use’. Such claims do not purport to claim a process (i.e. a method), machine, manufacture (i.e. a product), or composition of matter and fail to comply with 35 U.S.C. 101. See MPEP 2173.05(q).
Claims 7 & 14 are rejected under 35 U.S.C. 101 because the claimed invention is directed to naturally occurring proteins and their encoding genes (i.e. a natural phenomenon or product of nature) without significantly more.
The claims appear to be directed to a process and recite ‘an application of the protein’ or ‘an application of the gene’ with reference to native sequences from soybean.
These claims are directed to a natural phenomenon in that they recite the application of native sequences for improving plant symbiotic nitrogen fixation efficiency, which is the natural function of said sequences in nitrogen fixing plants.
This judicial exception is not integrated into a practical application because claims merely recite naturally occurring molecular sequences which are characterized (i.e. diagnosed) by Applicant. The claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception because claims 7 & 14 do not require any modification to the native gene or protein, do not involve generation of a transgenic or exogenous construct, and are not otherwise an inventive product of man. Furthermore, the recited function(s) of the claimed sequences are related to nitrogen fixation, which is the native function of said genes/proteins.
Because of this, claims 7 & 14 are merely claims to a natural phenomenon, being naturally occurring sequences associated with genes or allelic forms of GmNAS1 in Glycine, and are rejected as not being eligible subject matter.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 7-10 & 14-17 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
The claims recite ‘an application’ of the protein or encoding GmNAS1 gene. Applicant does not define or describe what is meant by ‘an application’ or clarify methods limited to by such claims. Recitation of ‘an application’ in the claims appears to be synonymous with ‘a use’. Such claims do not purport to claim a process (i.e. a method), machine, manufacture (i.e. a product), or composition of matter and fail to comply with 35 U.S.C. 101. See MPEP 2173.05(q).
As such, the metes and bounds of these claims and how one would avoid unintentionally infringing is unclear. Because of this, claims are rejected as indefinite.
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 7-10 & 14-17 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claims contain subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention.
Independent claims 7, 8 & 14-15 recite applications of proteins and encoding genes, or overexpression thereof, which increase plant yield(s). All other claims depend from these limitations.
Regarding impact of claimed genes on any and all plants.
Claims 7, 8 & 14-15 are drawn to use of Applicant’s claimed genes and proteins in plants. Broadest reasonable interpretation of these claims is that the invention functions in any and all plants. However, review of the specification indicates that Applicant’s disclosure is specific to plants with nodules that support nitrogen-fixing bacteria, and moreover, is only demonstrated in soybean cells [¶.19, 75 & 95]. Cross-species manipulation of genes involved in nitrogen fixation is known to be unpredictable, and moreover, it is unclear how a gene specific to a nitrogen-fixing legume such as soybean which forms root nodules would function in plant species which do not inherently fix nitrogen, exhibit nitrogenase activity, or make root nodules [see review in Pankievicz et al. BMC Biology (2019) 17:99; Pub. 3 Dec 2019].
As such, Applicant’s disclosure does not support that at the time of filing they were in possession of an inventive method which would be applicable in any and all plants.
Regarding impact of claimed genes on agronomics and/or yield.
Claims 7 & 14 are drawn to the effects of the native gene and/or encoded protein for ‘enhancing plant environmental adaptability and increasing plant yields’. At the time of filing, Applicant did not describe manipulation or methods of using the claimed genes with respect to their effect on soybean yield, or agronomics generally. Applicant limits description of gene effects to the trait of nitrogenase activity. Review of the specification provides examples of loss-of-function of the claimed gene/protein and its effect in altering nitrogenase activity in cell cultures but lacks description of overexpression or impact on any agronomic characteristics [¶.74-95, ¶.128].
Applicant does not overexpress gene(s) in transgenic, multicellular plants and it is unclear if such a construct would predictably function to improve yield. Because Applicant only presents limited example of biochemical assay effect(s) in a reductionist cell culture system, it is unclear if such nitrogenase effects would result in the claimed improved agronomics in a transgenic soybean plant. Research has shown that overexpression of transgenes is unpredictable; characterization of native gene function does not always indicate its use in overexpression constructs will work due to the unpredictability of transgene inactivation and/or variable expression effects in multicellular plants [see p.1, col.1, ¶2—p.3, col.1, ¶.4 in Sareen et al. ScienceJet 2014, 3:64; Pub. 29 Apr 2014]. As such, initial observations of differential nitrogenase activity in cell cultures would reasonably require testing or validation in whole-plant systems, with concurrent reporting of agronomic effects, to determine whether there is a predictable impact of such genetic manipulations.
Regarding function of overexpression vectors of GmNAS1.
Claims 8-10 & 15-17 are drawn to the effects of ‘application of [an] overexpression vector’ involving the native GmNAS1 gene and/or encoded protein that increase plant yields. Applicant did not describe or validate the effect of methods of overexpressing the claimed sequence(s) on either biochemical activity or agronomics. Review of the specification provides examples of loss-of-function of the claimed gene/protein and its effect in altering nitrogenase in cell cultures [¶.74-95, ¶.128]. Applicant does not overexpress gene(s) in transgenic, multicellular plants and it is unclear if such a construct would predictably function to improve yield. Research has shown genes are unpredictable when overexpressed as transgenes [id].
As such, the subject matter was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor had possession of the claimed invention.
Applicant is advised to amend their claims to reflect biological systems or phenotypes which they fully describe in their disclosure and they have confirmed function as expected.
Conclusion
No claims are allowed.
Contact Information
Any inquiry concerning this communication or earlier communications from the examiner should be directed to KEITH R WILLIAMS whose telephone number is (571)272-3911. The examiner can normally be reached Mon - Fri, 9:30 - 5:30 EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amjad Abraham can be reached on (571)270-7058. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/KEITH R. WILLIAMS/Examiner, Art Unit 1663
/Amjad Abraham/SPE, Art Unit 1663